Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may have overestimated the market for its new weight-loss and diabetes medicines.

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under anesthesia.

In general, when a person prepares for a surgery, the guidance is to fast before going under anesthesia– but for patients, on gGLP-1's there may still be gastric juices, in the stomach, since the drugs slow down the process of emptying the stomach.